Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025

July 2020 | 1740 pages | ID: G1C587A5522DEN
PNS Pharma

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025' Report Highlights:

• Global Leukemia Drug Market Opportunity: More Than US$ 22 Billion by 2025
• Comprehensive Insight on Leukemia Drug Clinical Trials: 633 Drugs
• Leukemia Drug Clinical Pipeline Insight by Company, Drug Class, Patent
• Comprehensive Clinical Insight on Marketed Leukemia Drug: 77 Drugs
• Marketed Leukemia Drug Insight by Drug Class: Availability, Dosage & Price Analysis
• Global Drug Development Partnerships & Collaboration Insight

'Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025' offers comprehensive insights on the various clinical and non-clinical parameters responsible for growth of global leukemia drug market. The emergence of new technological innovations in clinical research and drug development methodologies has led to the desired thrust to the market in recent years. This in-depth study enables its readers to identify and let them aware about the ongoing clinical trials, marketed drug dosage and price analysis, market advancements and associated commercial opportunities offered in the form of detailed analysis and graphical information presented in the report. As per report findings the market is expected to witness almost 60% absolute growth in next 6 years (2020-2025) and is estimated to surpass US$ 22 Billion by 2025.

The market is currently anticipated to be growth driven by many potential therapies as well as hundreds of ongoing clinical trials. There are more than 600 drugs in clinical trials and more than 70 drugs are commercially available in the market. The various advantages that are further adjoined by the market: private and public funding, innovative technologies and advancement such as artificial intelligence are classified as fundamentals for transforming the market status in a small period of time. The market has been more concentrated towards promoting the entry of small pharmaceutical companies into it such that it will seamlessly reduce the efforts given by single or few pharmaceutical companies involved in it.

The primary aim of the market is to develop novel patient centric candidates and collection of data at global level in order to predict the future course of action for the market. This is getting targeted to level down the potential challenges that could come across in the future. The insights of the market with respect to latest trends and challenges provides an overview about the substantial growth of the market as factors such as strong clinical pipeline, ongoing partnerships and collaborations and involvement of elite research and educational centers are powered together in order to fuel the leukemia therapy development. The market is collectively boosted by the presence of digital technology as well as advanced analytics for improving the clinical research and development productivity.

The ongoing clinical trials driven by revolutionized research based work have started offering dynamic opportunities towards patient centric approach in the market. It is estimated that the adoption of some changes in the regulatory system will expand the market in the next decade. The same is also accompanied by the emergence of technological innovations which has apparently resulted in the development of novel immunotherapy for the patients. All the advantages that are associated with the market have made it more efficient as well as effective. Currently, a wide range of anticancer drugs are used for the management of leukemia including Kinase inhibitors, BTK Inhibitors, monoclonal antibodies, antimetabolites, T-cell therapy, Interferons etc. while many new therapeutics are under investigation. Further, orphan drug designation and fast track approvals are also granted to many drugs by FDA, which is indicating a huge market potential of this segment in upcoming years.

Many leading pharmaceutical companies are adopting key strategies including acquisitions and new product launches, which generates new opportunities in leukemia drug market. In addition to this, the investments related to research and development of novel cancer therapeutics is increasing rapidly and many new drugs targeting leukemia are in late stage of clinical trial. Approval of these new drugs is expected in upcoming 1 to 2 years, which take this market to the next level. As per report findings, all the crucial trends that are associated with the leukemia market are making a huge impact on the overall development of the leukemia drugs. It is speeding the way of launch of novel and much needed medicines for the patients who are suffering from leukemia. Steps from incorporation of smart technologies in research to development of novel therapies for leukemia are pointing towards a more efficient as well as cost-effective solutions for millions of patients at global level.

Contents

1. INTRODUCTION TO LEUKEMIA

1.1 Overview
1.2 History: Initial Description & Origin of Leukemia

2. RELEVANCE OF LEUKEMIA THERAPEUTICS IN PHARMACEUTICAL MARKET

3. COMMERCIALLY AVAILABLE TREATMENTS & ITS IMPACT ON THE GLOBAL LEUKEMIA THERAPEUTICS MARKET

4. LEUKEMIA THERAPEUTICS MARKET GROWTH WITH CHEMOTHERAPY DRUGS

4.1 Overview
4.2 Mechanism of Action of Chemotherapy Drugs towards Leukemia Cancer Cells

5. IMMUNOTHERAPY CANDIDATES PROMISING ATTRIBUTE TOWARDS GLOBAL LEUKEMIA THERAPEUTICS MARKET

5.1 Overview
5.2 Mechanism of Action of Immunotherapy against Leukemia Cells

6. SMALL MOLECULE CANCER DRUGS EVOLVING GLOBAL LEUKEMIA THERAPEUTICS MARKET

6.1 Overview
6.2 Mechanism of Action of Small Molecule Cancer Drugs towards Leukemia
Treatment

7. GLOBAL IMPACT OF BONE MARROW TRANSPLANTATION ON LEUKEMIA THERAPEUTICS MARKET

7.1 Overview
7.2 Mechanism of Action of Bone Marrow Transplantation in Leukemia Patients

8. RADIATION THERAPY IMPACT ON THE GLOBAL LEUKEMIA THERAPEUTICS MARKET GROWTH

8.1 Overview
8.2 Mechanism of Action of Radiation Therapy for Leukemia Treatment

9. ONGOING CLINICAL RESEARCH DEVELOPMENT FOR LEUKEMIA THERAPEUTICS

9.1 UCLA to Combine Two Therapies to Leukemia Treatment Platform Available
9.2 CAR-T Cell Trials for Common Leukemia & Lymphoma Types led by UCLA
9.3 LILRB4, A New Potential Target for Leukemia Focused by UT Southwestern
Researchers
9.4 Phase Ib/II Trial Result for IDH1-Mutated Acute Myeloid Leukemia by University
of Texas M. D. Anderson Cancer Center
9.5 CAR-NK Cell Therapy for Clinical Trials Results for chronic lymphocytic
leukemia by The University of Texas MD Anderson Cancer Center
9.6 Takeda’s Phase II Trial of Pevonedistat & Azacitidine in Patients with Leukemia

10. GLOBAL PARTNERSHIPS & COLLABORATION INSIGHTS FOR DEVELOPMENT OF LEUKEMIA THERAPEUTICS

10.1 Piramal Pharma Solutions & BerGenBio to Undergo FDA Fast Track Leukemia
Treatment Development
10.2 Pascal Biosciences and Y-Biologics to Develop Bispecific Antibody for
Leukemia Treatment
10.3 Daiichi Sankyo & MD Anderson Collaboration for Accelerated Development of
Acute Myeloid Leukemia Therapies
10.4 Merck & Harvard to Undergo Collaboration for Developing Small Molecule
Drugs for Acute Myeloid Leukemia
10.5 JZP-458 Pivotal Phase 2/3 for Acute Lymphoblastic Leukemia Study Initiation
Announcement by Jazz Pharmaceuticals

11. GLOBAL LEUKEMIA THERAPEUTICS MARKET MARKET OVERVIEW

12. REGIONAL LEUKEMIA THERAPEUTICS MARKET ANALYSIS

12.1 US
12.2 European Union
12.3 Asia
12.4 Middle East & Africa

13. GLOBAL LEUKEMIA DRUG CLINICAL TRIALS OVERVIEW

13.1 By Phase
13.2 By Country
13.3 By Drug Class
13.4 By Company/Clinic
13.5 By Patient Segment

14. ANTINEOPLASTIC DRUGS FOR LEUKEMIA – AVAILABILITY, DOSAGE & PRICE ANALYSIS

14.1 Azacitidine (Vidaza)
14.2 Venetoclax (Venclexta)
14.3 Enasidenib (Idhifa)
14.4 Tretinoin (Vesanoid)
14.5 Histamine Dihydrochloride Injection (Ceplene)
14.6 Ubenimix (Bestatin)
14.7 Arsenic Trioxide (Trisenox)
14.8 Tamibarotene (Amnolake)
14.9 Amsacrine (Amsa PD/Amekrin)
14.10 Immune Globulin (Gammagard Liquid, Gammagard S/D, Cuvitru & HyQvia)
14.11 Crisantaspase (Erwinase)
14.12 Pegaspargase (Oncaspar)
14.13 Calaspargase Pegol (Asparlas)
14.14 Asparaginase (Elspar/Kidrolase/Leunase)
14.15 Sobuzoxane (Perazolin)

15. MULTIKINASE INHIBITOR DRUGS FOR LEUKEMIA – AVAILABILITY, DOSAGE, & PRICE ANALYSIS

15.1 Gilteritinib (Xospata)

16. TYROSINE KINASE INHIBITORS FOR LEUKEMIA – AVAILABILITY, DOSAGE, & PRICE ANALYSIS

16.1 Bosutinib (Bosulif)
16.2 Dasatinib (Sprycel)
16.3 Ponatinib (Iclusig)
16.4 Nilotinib (Tasigna)
16.5 Quizartinib (Vanflyta)
16.6 Radotinib (Supect)
16.7 Imatinib (Gleevec)

17. COMBINATIONAL ANTINEOPLASTIC DRUGS FOR LEUKEMIA – AVAILABILITY, DOSAGE & PRICE ANALYSIS

17.1 Cytarabine/Daunorubicin (Vyxeos)
17.2 Ivosidenib (Tibsovo)
17.3 Rituxan Hycela (hyaluronidase/rituximab)

18. ANTIMETABOLITES FOR LEUKEMIA – AVAILABILITY, DOSAGE & PRICE ANALYSIS

18.1 Cladribine (Mavenclad/Leustatin)
18.2 Clofarabine (Clolar)
18.3 Mercaptopurine Oral Suspension (Purixan)
18.4 Methotrexate Oral Solution (Xatmep)
18.5 Decitabine (Decogen)
18.6 Nelarabine (Arranon)
18.7 Fludarabin (Fludara/Oforta)
18.8 Methotrexate

19. ANTICANCER ANTIBIOTICS FOR LEUKEMIA – AVAILABILITY, DOSAGE & PRICE ANALYSIS

19.1 Pentostatin (Nipent)
19.2 Mitoxantrone (Novantrone)
19.3 Idarubicin (Idamycin)

20. PHOSPHOINOSITIDE 3-KINASE INHIBITORS – AVAILABILITY, DOSAGE & PRICE ANALYSIS

20.1 Duvelisib (Copiktra)
20.2 Idelalisib (Zydelig)

21. ALKYLATING AGENTS FOR LEUKEMIA – AVAILABILITY, DOSAGE & PRICE ANALYSIS

21.1 Bendamustine (Treanda/Belrapzo/Bendeka)
21.2 Cyclophosphamide
21.3 Dianhydrogalactitol (DAG for Injection)

22. BRUTON TYROSINE KINASE (BTK) INHIBITORS FOR LEUKEMIA – AVAILABILITY, DOSAGE, & PRICE ANALYSIS

22.1 Ibrutinib (Imbruvica)

23. MONOCLONAL ANTIBODIES FOR LEUKEMIA – AVAILABILITY, DOSAGE, & PRICE ANALYSIS

23.1 Inotuzumab ozogamicin (Besponsa)
23.2 Gemtuzumab ozogamicin (Mylotarg)
23.3 Ofatumumab (Arzerra)
23.4 Gazyva (Obinutuzumab)
23.5 MabThera/Rituxan (Rituximab)
23.6 Blinatumomab (Blincyto)
23.7 Lumoxiti (Moxetumomab pasudotox)
23.8 Poteligeo (Mogamulizumab)
23.9 Rituximab Biosimilar (Truxima)
23.10 Rituximab Biosimilar (Ruxience)
23.11 Rituximab Biosimilar (Rixathon)
23.12 Rituximab Biosimilar - Acellbia
23.13 Rituximab Biosimilar - Maball
23.14 Rituximab Biosimilar - Mabtus
23.15 Rituximab Biosimilar - Zytux
23.16 Alemtuzumab (Campath)

24. T-CELL THERAPY FOR LEUKEMIA – AVAILABILITY, DOSAGE, & PRICE ANALYSIS

24.1 Tisagenlecleucel (Kymriah)
24.2 Nalotimagene Carmaleucel (Zalmoxis)

25. MITOTIC INHIBITORS FOR LEUKEMIA – AVAILABILITY, DOSAGE & PRICE ANALYSIS

25.1 Vincristine Liposomal (Marqibo)

26. ANTINEOPLASTIC INTERFERONS FOR LEUKEMIA – AVAILABILITY, DOSAGE & PRICE ANALYSIS

26.1 Interferon Alpha-2b (Intron A)
26.2 Interferon Alfa-2a (Roferon-A/Veldona)
26.3 Interferon Alpha (Multiferon)

27. GLOBAL LEUKAEMIA DRUG CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

27.1 Unknown
27.2 Research
27.3 Preclinical
27.4 Clinical
27.5 Phase-0
27.6 Phase-I
27.7 Phase-I/II
27.8 Phase-II
27.9 Phase-II/III
27.10 Phase-III
27.11 Preregistration
27.12 Registered

28. GLOBAL MARKETED LEUKAEMIA DRUG CLINICAL INSIGHT

29. GLOBAL LEUKEMIA THERAPEUTICS MARKET DYNAMICS

29.1 Global Leukemia Therapeutics Growth Attributors
29.2 Challenges Concerning the Growth of Leukemia Therapeutics Market at Global
Level

30. GLOBAL LEUKEMIA THERAPEUTICS MARKET FUTURE INSIGHTS

31. COMPETITIVE LANDSCAPE

31.1 AbbVie Inc
31.2 Bristol-Myers Squibb
31.3 Amgen
31.4 Genzyme Corporation
31.5 Pfizer
31.6 GlaxoSmithKline Plc
31.7 Novartis International AG
31.8 Teva Pharmaceuticals
31.9 Takeda Pharmaceuticals
31.10 Piramal Pharma Solutions

List Of Figures

LIST OF FIGURES

Figure 1-1: Blood Comparison of a Healthy Person & Leukemia Patient
Figure 1-2: Major Characteristics of Leukemia Subtypes
Figure 1-3: Comparison for Subtypes of Leukemia by Average Age of Diagnosis & 5-Year Survival Percentage
Figure 1-4: Contributors to the History of Leukemia
Figure 2-1: Available Cancer Treatments for Leukemia in the Market
Figure 2-2: Global – Leukemia Death Statistics, 2018
Figure 3-1: Cancer Types vs. Leukemia Cancer Treatments
Figure 4-1: Treanda – Total Sales (US$ Million), 2016 - 2019
Figure 4-2: Tasigna – Total Sales (US$ Million), 2016 - 2019
Figure 4-3: Global – Total vs. Active, not Recruiting Chemotherapy Clinical Trials, 2020
Figure 4-4: Mechanism of Action of Chemotherapeutic Drugs on Leukemia Cells
Figure 5-1: Global – Kymriah Total Sales (US$ Million), 2017 - 2019
Figure 5-2: Global – Total vs. Active, not Recruiting Immunotherapy Clinical Trials for Leukemia, 2020
Figure 5-3: Outcomes Anticipated by the Arrival of Immunotherapy Treatment for Leukemic Patients
Figure 5-4: Mechanism of Action of Immunotherapy on Leukemia Cells
Figure 6-1: Properties of Small Molecule Cancer Drugs
Figure 6-2: Global – Gleevec Total Sales (US$ Million), 2018 & 2019
Figure 6-3: Mechanism of Action of Small Molecule Cancer Drugs on Leukemia Cells
Figure 7-1: Global – Total vs. Active, not Recruiting Bone Marrow Transplantation Clinical Trials, 2020
Figure 7-2: Global –Bone Marrow Transplantation Market (US$ Billion), 2018 - 2025
Figure 7-3: Mechanism of Action of Bone Marrow Transplantation in Leukemia Patients
Figure 8-1: Radiation Therapy – Clinical Trials for Leukemia Subtypes, 2020
Figure 8-2: Mechanism of Action of Radiation Therapy for Leukemia Patients
Figure 11-1: Global - Leukemia Market (US$ Billion), 2019 - 2025
Figure 12-1: US – Leukemia Statistics, 2018
Figure 12-2: US – Total vs. Active Leukemia Clinical Trials, 2020
Figure 12-3: US - Rising Parameters for Leukemia Therapeutics Market
Figure 12-4: Europe – Leukemia Statistics, 2018
Figure 12-5: Europe – Total Leukemia Clinical Trials, 2020
Figure 12-6: Europe - Important Parameters for Leukemia Market Growth
Figure 12-7: Asia – Leukemia Statistics, 2018
Figure 12-8: China – Total vs. Active, not Recruiting Leukemia Clinical Trials, 2020
Figure 12-9: Asia – Parameters Contributing to the Current Leukemia Therapeutics Market Status
Figure 13-1: Global - Leukemia Drug Clinical Pipeline by Phase(%), 2019 till 2025
Figure 13-2: Global - Leukemia Drug Clinical Pipeline by Phase(Number of Drugs), 2019 till 2025
Figure 13-3: Global - Leukemia Drug Clinical Pipeline by Country(Number of Drugs), 2019 till 2025
Figure 13-4: Global - Leukemia Drug Clinical Pipeline by Drug Class (Number of Drugs), 2019 till 2025
Figure 13-5: Global - Leukemia Drug Clinical Pipeline by Company/Clinic (Number of Drugs), 2019 till 2025
Figure 13-6: Global - Leukemia Drug Clinical Pipeline by Patient segment (Number of Drugs), 2019 till 2025
Figure 14-1: Vidaza – FDA & First generic Approval Year
Figure 14-2: Vidaza – Branded v/s Generic Price for 100mg Intravenous powder (US$), May’2020
Figure 14-3: Vidaza – Dose for Initial & Subsequent Treatment Cycle (mg/m2)
Figure 14-4: Vidaza – Cost of Initial & Subsequent Treatment Cycle (US$), May’2020
Figure 14-5: Venetoclax - Patent Issue & Expiration year
Figure 14-6: Venetoclax – Price for Various Supplies of 10mg Tablet (US$), June’2020
Figure 14-7: Venetoclax – Price for Various Supplies of 50mg Tablet (US$), June’2020
Figure 14-8: Venetoclax – Price for Various Supplies of 50mg Tablet (US$), June’2020
Figure 14-9: Venetoclax – Price for 42 Kit & Price per unit Kit (US$), June’2020
Figure 14-10: Venetoclax Monotherapy – Recommended Dose by Treatment Week for CLL Management (mg/day), June’2020
Figure 14-11: Venetoclax Combinational – Recommended Dose in Initial & Subsequent Treatment Cycle for CLL (mg/Cycle), June’2020
Figure 14-12: Venetoclax Monotherapy – Recommended Dose for AML (mg/day), May’2020
Figure 14-13: Venclexta – Annual Sales Value (US$ Million), 2017 - 2019
Figure 14-14: Venclexta - Annual Sales Value by Region (US$ Million), 2019
Figure 14-15: Venclexta – Annual Sales Value by Region (%), 2019
Figure 14-16: Global - Venclexta Quarterly Sales Value (US$ Million), 2019
Figure 14-17: Idhifa – Patent Issue & Expiration Year
Figure 14-18: Idhifa – Price for 30 Tablets & Price per unit of Oral Tablet (US$), June’2020
Figure 14-19: Idhifa – Daily & Full Treatment Cost (US$), June’2020
Figure 14-20: Idhifa – Annual Sales Value (US$ Million), 2017 & 2018
Figure 14-21: Idhifa – US v/s Rest of World Annual Sales Value (US$ Million), 2019
Figure 14-22: Idhifa – US v/s Rest of World Annual Sales Value (%), 2019
Figure 14-23: Idhifa – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 14-24: Vesanoid – FDA Approval & First Generic Approval Year
Figure 14-25: Tretinoin – price for 30 Capsule Supply 7 Price per Unit Capsule (US$), May’2020
Figure 14-26: Tretinoin – price for 100 Capsule Supply & Price per Unit Capsule (US$), May’2020
Figure 14-27: Tretinoin – Minimum & Maximum Treatment Cost (US$), June’2020
Figure 14-28: Ceplene – Europe Market Authorisation & Orphan Designation Year
Figure 14-29: Ceplene – Cost of Single Administration, Single Day Treatment & One Treatment Cycle (US$/GBP), June’2020
Figure 14-30: Trisenox – FDA Approval Year by Strength
Figure 14-31: Trisenox – FDA Approval & First Generic Approval Year
Figure 14-32: Arsenic Trioxide – Price for 100ml Supply & Price per ml of Branded & Generic Intravenous Solution of 1mg/ml Dose, June’2020
Figure 14-33: Arsenic Trioxide – Price for 60ml Supply & Price per ml of Branded & Generic Intravenous Solution of 2mg/ml Dose (US$), June’2020
Figure 14-34: Arsenic Trioxide – Duration of Induction & Consolidation Treatment Cycle (Days)
Figure 14-35: Arsenic Trioxide – Number of Required Induction & Consolidation Treatment Cycle
Figure 14-36: Amnolake – PMDA Approval & Patent Expiration Year
Figure 14-37: Amsacrine – Minimum & Maximum Recommended Dose (mg/m2)
Figure 14-38: Immune Globulin – FDA Approval Year by Brand Name
Figure 14-39: Cuvitru – Price for 1 & 5 ml Supply of 20% Solution (US$), June’2020
Figure 14-40: Cuvitru – Price for 1 & 10 ml Supply of 20% Solution (US$), June’2020
Figure 14-41: Cuvitru – Price for 1 & 20 ml Supply of 20% Solution (US$), June’2020
Figure 14-42: Cuvitru – Price for 1 & 40 ml Supply of 20% Solution (US$), June’2020
Figure 14-43: Cuvitru – Price for 1 & 50 ml of 20% Solution (US$), June’2020
Figure 14-44: Gammagard S/D – Price for 5gm and 10gm Powder for Injection (US$), June’2020
Figure 14-45: Gammagard Liquid – Price for Various Supplies of Solution (US$), June’2020
Figure 14-46: Hyqvia – Price for Various Supplies of Subcutaneous Solution (US$), June’2020
Figure 14-47: Immuno Globulin – Minimum & Maximum Duration of Treatment Cycle (Weeks)
Figure 14-48: Erwinase – Price for Supply of 5 Powders & Price per unit of 10,000 IU Powder for Injection (US$), June’2020
Figure 14-49: Erwinase – Average Cost of Single Administration & Full Treatment Cost (US$), June’2020
Figure 14-50: Global - Erwinase Annual sales Value (US$ Million), 2017 - 2019
Figure 14-51: Global - Erwinase Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 14-52: Oncaspar – FDA & EMA Approval Year
Figure 14-53: Oncaspar – US & Europe Exclusivity Expiration Year
Figure 14-54: Oncaspar – Price for 5 ml Supply & Price per ml of Injectable Solution (US$), June’2020
Figure 14-55: Oncaspar – Recommended Dose by Age (IU/m2 once in 2 Weeks)
Figure 14-56: Asparlas – Price for 1 & 5 mL Solution of Dose 750 units/mL (US$), June’2020
Figure 14-57: Oncaspar – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$)
Figure 14-58: Leunase – Price for 10000IU & 5000IU Powder for Injection (INR/US$), June’2020
Figure 14-59: Leunase – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$)
Figure 15-1: Xospata – Patent Issue Expiration Year
Figure 15-2: Xospata – Price for 30 Tablets & Price per unit Tablet (US$), May’2020
Figure 15-3: Xospata – Daily, Monthly & Annual Treatment Cost (US$), May’2020
Figure 15-4: Global - Xospata Quarterly Sales Value (JPY/US$ Million), 2018 & 2019
Figure 16-1: Bosulif – Patent Issue & Expiration Year
Figure 16-2: Bosulif – Price for 120 Tablet & Price per Unit of 100mg Tablet (US$), June’2020
Figure 16-3: Bosulif – Price for 30 Tablet & Price per Unit of 400 & 500mg Tablet (US$), June’2020
Figure 16-4: Bosulif – Recommended Dose for Newly Diagnosed & Therapy Resisted CML (mg)
Figure 16-5: Sprycel – FDA Approval Year by Tablet Strength
Figure 16-6: Sprycel – Patent Issue & Expiration Year
Figure 16-7: Sprycel – Price for 60 Tablets & Price per Unit Tablet of 20mg, 50mg and 70mg (US$), June’2020
Figure 16-8: Sprycel – Price for 30 Tablets & Price per Unit Tablet of 80mg, 100mg and 140mg (US$), June’2020
Figure 16-9: Sprycel – Recommended Dose by Indication (mg/day)
Figure 16-10: Sprycel – Recommended Pediatric Dose by Weight (mg/day)
Figure 16-11: Iclusig – FDA Approval Year by Tablet Strength (US$), June’2020
Figure 16-12: Iclusig - Patent Issue & Expiration Year
Figure 16-13: Iclusig – Price for 30 tablets & Price per unit Tablet of 15mg & 45mg (US$), June’2020
Figure 16-14: Iclusig – Recommended Initial & Reduced Dose (mg/day)
Figure 16-15: Iclusig – Global Sales Value (US$ Million), 2018 & 2019
Figure 16-16: Global - Iclusig Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 16-17: Tasigna – FDA Approval Year by Indication
Figure 16-18: Tasigna – Patent Issue & Expiration Year
Figure 16-19: Tasigna – Price for 120 Capsules & Price per unit Capsule of 50mg (US$), June’2020
Figure 16-20: Tasigna – Price for 28 & 112 Capsules & Price per unit Capsule of 100 & 200 mg (US$), June’2020
Figure 16-21: Tasigna – Recommended Dose by Indication (mg Twice Daily), June’2020
Figure 16-22: Tasigna – Recommended Pediatric Dose by Surface Area (mg Twice Daily), May’2020
Figure 16-23: Vanflyta– Recommended Dose for AML Treatment (mg/day)
Figure 16-24: Vanflyta– Recommended Dose & Dose after Reduction (mg/day)
Figure 16-25: Supect – Daily, Monthly & Annual Treatment Cost (US$), June’2020
Figure 16-26: Gleevec – FDA Approval by Dosage Form
Figure 16-27: Gleevec – FDA Approval by Indication
Figure 16-28: Gleevec – Patent Issue & Expiration Year
Figure 16-29: Imatinib – Price for 30 Tablet supply of Branded & Generic Imatinib 400mg (US$), June’2020
Figure 16-30: Imatinib – Price for 90 Tablet supply of Branded & Generic Imatinib 400mg (US$), June’2020
Figure 16-31: Gleevec – Recommended Dose by Indication (mg/Day)
Figure 17-1: Vyxeos – FDA Approval & Patent Expiration Year
Figure 17-2: Vyxeos – Price for 1, 2 & 5 Powder for Injection (US$), June’2020
Figure 17-3: Vyxeos – Number of Drug Administration Required in Different Treatment Cycles (Dose/Cycle), June’2020
Figure 17-4: Tibsovo – FDA Approval Year by Indication
Figure 17-5: Tibsovo – Patent Issue & Expiration Year
Figure 17-6: Tibsovo – Price for 60 Tablets & Price per unit of 250mg Tablet (US$), May’2020
Figure 17-7: Tibsovo – Cost of Daily Treatment & Full Treatment Cost (US$), May’2020
Figure 17-8: Global – Tibsovo Sales Value (US$ Million), 2018 & 2019
Figure 17-9: Global – Tibsovo Quarterly Sales Value (US$ Million), 2019
Figure 17-10: Rituxan Hycela – FDA Approval & Patent Expiration Year
Figure 17-11: Rituxan Hycela – Price for 11.7 ml Supply & Price per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), February’2020
Figure 17-12: Rituxan Hycela – Price for 13.4 ml Supply & Price per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), February’2020
Figure 17-13: Rituxan Hycela – Duration of CLL Treatment (Weeks), June’2020
Figure 17-14: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), June’2020
Figure 18-1: Cladribine – FDA Approval Year by Brand Name
Figure 18-2: Mavenclad – Merck’s Patent Issue & Expiration Year
Figure 18-3: Mavenclad – Ares Trading’s Patent Issue & Expiration Year
Figure 18-4: Mavenclad – Price for various Tablet Supplies of 10mg (US$), June’2020
Figure 18-5: Generic Cladribine – Price for 10 & 1ml Intravenous Solution (US$), June’2020
Figure 18-6: Cladribine – Recommended Dose by Route of Administration (mg/Kg/day)
Figure 18-7: Clolar – FDA Approval & First Generic Approval Year
Figure 18-8: Clolar – Price for 20ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 18-9: Generic Clofarabine – Price for 20ml Supply & Price per ml of Intravenous Solution (US$), May’2020
Figure 18-10: Clolar – Recommended dose & Dose after Reduction (mg/m2/day)
Figure 18-11: Purixan – FDA Approval & Exclusivity Expiration Year
Figure 18-12: Purixan – Price for 100ml Supply & Price per ml of Oral Suspension (US$), June’2020
Figure 18-13: Purixan – Minimum & Maximum Recommended Dose (mg/Kg)
Figure 18-14: Xatmep – Patent Issue & Expiration Year
Figure 18-15: Xatmep – Price for 60ml Supply & Price per ml of Oral Solution (US$), June’2020
Figure 18-16: Xatmep – Price for 100ml Supply & Price per ml of Oral Solution (US$), June’2020
Figure 18-17: Xatmep – Cost of Single Treatment Cycle & Annual Treatment Cost (US$), June’2020
Figure 18-18: Decogen – FDA Approval & first Generic Approval Year
Figure 18-19: Decitabine – Price for 50mg Branded & Generic Intravenous Powder (US$), June’2020
Figure 18-20: Decitabine – Cost of Single Dose, Single day & Single Treatment Cycle using 15mg/m2/Thrice a Day Dose regimen (US$), June’2020
Figure 18-21: Decitabine – Cost of Single Day & Single Treatment Cycle using 20mg/m2/Daily Dose regimen (US$), June’2020
Figure 18-22: Arranon – FDA Approval Year & Patent Expiration Year
Figure 18-23: Arranon – Price for 50ml & 300ml intravenous Solution of 5mg/ml Dose (US$), June’2020
Figure 18-24: Arranon – Adult & Pediatric Dose (mg/m2)
Figure 18-25: Fludarabin – FDA Approval Year by Brand Name
Figure 18-26: Fludarabin – Price for 50mg Intravenous Powder & 2 ml Intravenous Solution for Injection (US$), May’2020
Figure 18-27: Methotrexate – Average Price of 10 ml Supply & Price per ml of 25mg/ml Intravenous Solution (US$), June’2020
Figure 18-28: Methotrexate – Average Price of Different Supplies of Oral Tablet (US$), June’2020
Figure 18-29: Methotrexate – Minimum & Maximum Duration of Initial Treatment Phase of ALL (Weeks), June’2020
Figure 18-30: Methotrexate – Single Treatment Cycle Cost in Initial & Maintenance Phase (US$), June’2020
Figure 18-31: Methotrexate – Minimum & Maximum Treatment Cost of Initial Phase of ALL (US$), June’2020
Figure 18-32: Methotrexate – Duration of Treatment & Rest Period for Choriocarcinoma Treatment (Days), June’2020
Figure 18-33: Methotrexate – Minimum & Maximum Treatment Cost of Single Day (US$), June’2020
Figure 18-34: Methotrexate – Minimum & Maximum Cost of Single Treatment Cycle (US$), June’2020
Figure 19-1: Nipent – FDA Approval & First Generic Approval Year
Figure 19-2: Pentostatin – Price for Single Vial of Generic & Branded Pentostatin (US$), May’2020
Figure 19-3: Mitoxantron – FDA Approval & First Generic Approval Year
Figure 19-4: Mitoxantron – Price for 10ml, 12.5ml & 15 ml Supply of 2mg/ml Intravenous Solution (US$), June 2020
Figure 19-5: Mitoxantron – Minimum & Maximum Dose for Prostate Cancer (mg/3weeks)
Figure 19-6: Idarubicin - FDA & First Generic Approval Year
Figure 19-7: Idarubicine – Price Comparision of 5ml Intravenous Branded & Generic Solution (US$), June’2020
Figure 19-8: Idarubicine – Price Comparision of 10ml Intravenous Branded & Generic Solution (US$), June’2020
Figure 19-9: Idarubicine – Price Comparision of 20ml Intravenous Branded & Generic Solution (US$), June’2020
Figure 19-10: Idarubicin – Dialy & Maximum Cumulative Lifetime Dose (mg/m2), January’2020
Figure 19-11: Idarubicin – Comparision of Dialy & Full Treatment Cost uisng Branded & Generic Tablet (US$), January’2020
Figure 20-1: Copiktra – Interllikine’s Patent Issue & Expiration Year
Figure 20-2: Copiktra – Infinity Pharma’s Patent Issue & Expiration Year
Figure 20-3: Copiktra – Price for 56 Capsules Supply & Price per unit Capsule (US$), June’2020
Figure 20-4: Copiktra – Recommended & Reduced Dose (mg/day)
Figure 20-5: Zydelig – Number of Patents by Assignee
Figure 20-6: Zydelig – Patent Expiration Year by Assignee
Figure 20-7: Zydelig – Price for 60 Tablet Supply & Price per Unit Tablet (US$), June’2020
Figure 20-8: Zydelig – Recommended & Reduced Dose (mg/day)
Figure 20-9: Global - Zydelig Sales Value (US$ Million), 2017 - 2019
Figure 20-10: Zydelig – Annual Sales Value by Region (US$ Million), 2019
Figure 20-11: Zydelig – Annual Sales Value by Region (%), 2019
Figure 20-12: Zydelig – Quarterly Sales Value (US$ Million), 2018 - 2019
Figure 21-1: Bendamustine – FDA Approval Year by Brand Name
Figure 21-2: Treanda – Patent Issue & Expiration Year
Figure 21-3: Bendeka – Number of Patent by Assignee
Figure 21-4: Bendeka – Patent Expiration Year by Assignee
Figure 21-5: Bendamustine – FDA & First Generic Approval Year
Figure 21-6: Bendamustine – Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 21-7: Bendeka – Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 21-8: Belrapzo – Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 21-9: Bendamustine – Comparision of Treatment Cost of CLL uisng Branded & Generic Solution (US$), June’2020
Figure 21-10: Cyclophosphamide – FDA Approval Year by Companies
Figure 21-11: Cyclophosphamide – Average Price for 1gm, 2gm & 500mg Powder for Injection (US$), June’2020
Figure 21-12: Cyclophosphamide – Average Price for a Supply of 100 Capsules of 25mg & 50 mg Dose (US$), June’2020
Figure 21-13: Hikma’s Cyclophosphamide – Average Price for a Supply of 100 Capsules of 25mg Dose (US$), June’2020
Figure 21-14: Cyclophosphamide IV Solution – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June’2020
Figure 21-15: Cyclophosphamide Capsule – Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June’2020
Figure 22-1: Ibrutinib – FDA Approval Year by Indication
Figure 22-2: Ibrutinib – FDA Approval Year by Dosage Form
Figure 22-3: Imbruvica – Price for 90 & 120 Capsule Supplies of 140mg (US$), June’2020
Figure 22-4: Imbruvica Capsule – Price for 28 Capsule & Price Per unit Capsule of 70mg (US$), June’2020
Figure 22-5: Imbruvica Tablet – Price for 28 Tablets & Price Per unit Tablet of Various Doses (US$), June’2020
Figure 22-6: Imbruvica – Recommended Daily Dose by Indication (mg), May’2020
Figure 22-7: Imbruvica – Annual Sales Value (US$ Billion), 2017 - 2019
Figure 22-8: Imbruvica - Annual Sales Value by Region (US$ Million), 2019
Figure 22-9: Imbruvica – Annual Sales Value by Region (%), 2019
Figure 22-10: Global - Imbruvica Quarterly Sales Value (US$ Million), 2019
Figure 23-1: Besponsa – Orphan Market Exclusivity Issue & Expiration Year
Figure 23-2: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days), June’2020
Figure 23-3; Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2), June’2020
Figure 23-4: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), June’2020
Figure 23-5: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), June’2020
Figure 23-6: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks), June’2020
Figure 23-7: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year
Figure 23-8: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 23-9: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), June’2020
Figure 23-10: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML, June’2020
Figure 23-11: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days), June’2020
Figure 23-12: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2), June’2020
Figure 23-13: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), June’2020
Figure 23-14: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, June’2020
Figure 23-15: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), June’2020
Figure 23-16: Arzerra – Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), June’2020
Figure 23-17: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg), June’2020
Figure 23-18: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), June’2020
Figure 23-19: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), June’2020
Figure 23-20: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg), June’2020
Figure 23-21: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), June’2020
Figure 23-22: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg), June’2020
Figure 23-23: Arzerra – Treatment Duration for Refractory CLL (Weeks), June’2020
Figure 23-24: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), June’2020
Figure 23-25: Gazyva – Approval Year by Non-Hodgkin’s Lymphoma Type
Figure 23-26: Gazyva – Price for 40ml Supply & Price per ml of Intravenous Solution (US$), June’2020
Figure 23-27: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), June’2020
Figure 23-28: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week), June’2020
Figure 23-29: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), June’2020
Figure 23-30: Gazyva – Annual Sales Value (US$/CHF Million), 2016 - 2019
Figure 23-31: Global - Gazyva Quarterly Sales Value (US$/CHF Million), 2018
Figure 23-32: Global - Gazyva Quarterly Sales Value (US$/CHF Million), 2019
Figure 23-33: US - Gazyva Quarterly Sales Value (US$ Million), 2019
Figure 23-34: Gazyva – Annual Sales Value by Region (CHF/US$ Million), 2019
Figure 23-35: Gazyva – Annual Sales Value by Region (%), 2019
Figure 23-36: Gazyva – FDA Approval Year by Indication
Figure 23-37: Rituxan – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-38: Rituxan – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-39: Rituxan – Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-40: Rituxan – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-41: Rituxan – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-42: Rituxan – Annual Sales Value (US$/CHF Billion), 2017 - 2019
Figure 23-43: Global - Rituxan Quarterly Sales Value (US$ Billion), 2018 & 2019
Figure 23-44: US - Rituxan Quarterly Sales Value (US$/CHF Billion), 2019
Figure 23-45: Rituxan – Annual Sales Share of US & Rest of World (%), 2019
Figure 23-46: Rituxan – Annual Sales Value by Region (CHF/US$ Billion)), 2019
Figure 23-47: Rituxan – Annual Sales Value by Region (%), 2019
Figure 23-48: Blincyto – Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, June’2020
Figure 23-49: Blincyto – Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days), June’2020
Figure 23-50: Blincyto – Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), June’2020
Figure 23-51: Blincyto – Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, June’2020
Figure 23-52: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), June’2020
Figure 23-53: Blincyto – Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), June’2020
Figure 23-54: Blincyto – Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), June’2020
Figure 23-55: Global - Blincyto Sales Value (US$ Million), 2016 - 2019
Figure 23-56: Blincyto - Sales Value by Region (US$ Million), 2019
Figure 23-57: Blincyto - Sales Value by Region (%), 2019
Figure 23-58: Blincyto – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 23-59: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 23-60: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks), June’2020
Figure 23-61: Lumoxitin – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), June’2020
Figure 23-62: Poteligeo – FDA Approval & Patent Expiration Year
Figure 23-63: Poteligeo – Price for 5ml Supply & Price per unit of 4mg/ml Intravenous Solution (US$), June’2020
Figure 23-64: Poteligeo – Number of Dose Administration in Initial & Subsequent Treatment Cycle
Figure 23-65: Poteligeo – Cost of Single Dose, Initial & Subsequent Treatment Cycle (US$), June’2020
Figure 23-66: Japan - Poteligeo Sales Value (US$ Million), 2018 & 2019
Figure 23-67: Global - Poteligeo Sales Value (US$ Million), 2018 & 2019
Figure 23-68: Japan – Poteligeo Quarterly Sales Value (JPY/US$ Million), 2019
Figure 23-69: ROW – Poteligeo Quarterly Sales Value (JPY/US$ Million), 2019
Figure 23-70: Truxima – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-71: Truxima – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), June’2020
Figure 23-72: Truxima – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-73: Truxima – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-74: Ruxience – Price for 1 & 10 mL Solution of Dose 10 mg/mL (US$), June’2020
Figure 23-75: Ruxience – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-76: Ruxience – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-77: Rixathon – Price for Supply of 2 Vials & Price per unit Vial of 10ml Solution (GBP/US$), June’2020
Figure 23-78: Rixathon – Price for Supply of 2 Vials & Price per unit Vial of 50ml Solution (GBP/US$), June’2020
Figure 23-79: Rixathon – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-80: Ruxience – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-81: Acellbia – Price for Supply of 2 Vials & Price per unit Vial of 10ml Solution (INR/US$), June’2020
Figure 23-82: Acellbia – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-83: Acellbia – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-84: Maball – Price for Supply of 10ml & Price per ml of Injection (INR/US$), June’2020
Figure 23-85: Maball – Price for Supply of 50ml & Price per ml of Injection (INR/US$), June’2020
Figure 23-86: Acellbia – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-87: Acellbia – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-88: Mabtus – Price for Supply of 10ml & Price per ml of Injection (INR/US$), June’2020
Figure 23-89: Mabtus – Price for Supply of 50ml & Price per ml of Injection (INR/US$), June’2020
Figure 23-90: Mabtus – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-91: Mabtus – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-92: Zytux – Price for Supply of 2 Vail & Price per unit Vial of 10ml solution for Injection (LL/US$), June’2020
Figure 23-93: Zytux – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June’2020
Figure 23-94: Zytux – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 23-95: Campath – FDA Approval Year by Brand Name
Figure 23-96: Campath – Cost of Single Dose & Single Treatment Cycle (US$), June’2020
Figure 24-1: Kymriah – FDA approval Year by Cancer Type
Figure 24-2: Kymriah – Number of Patents in US, Europe & Japan
Figure 24-3: Kymriah – Cost of Acute Lymphoblastic Leukemia Treatment (US$ 000’), June’2020
Figure 24-4: Kymriah - Sales Value (US$ Million), 2017 - 2019
Figure 24-5: Kymriah – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 24-6: Synribo – Patent Issue & Expiration Year
Figure 24-7: Synribo – Treatment Phase in Induction & Maintenance Cycle (Weeks/Cycle)
Figure 24-8: Zalmoxis – Orphan Drug Designation & European Approval Year
Figure 24-9: Zalmoxis – Cost of Single Treatment Cycle & Full Treatment (EUR/US$), June’2020
Figure 25-1: Marqibo – FDA Approval & Patent Expiration Year
Figure 25-2: Marqibo – Recommended Dose & Dose after Reduction (mg/m2 Once Weekly)
Figure 26-1: Intron A – Price for a Supply of 10, 18 & 50 Million IU Powder for Injection (US$), June’2020
Figure 26-2: Intron A – Price for a Supply of 6 & 10 Million IU/ml Intravenous Solution (US$), June’2020
Figure 26-3: Intron A – Average Cost of Single Treatment Cycle for Hairy Cell Leukemia by Dosage Forms (US$), June’2020
Figure 26-4: Intron A – Average Cost of Full Treatment of Course Hairy Cell Leukemia by Dosage Forms (US$), June’2020
Figure 26-5: Roferon-A – Price for a Supply of 3 Million IU & 4.5 Million IU Syringe (INR/US$), June’2020
Figure 26-6: Roferon-A – Recommended Dose by Type of Leukemia (Million IU/ Day)
Figure 29-1: Drivers for Leukemia Therapeutics Market Growth